Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cardiovascular and Hematological Disorders - Drug Targets is Scopus-indexed (Q3, CiteScore 1.8). It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1871-529XVerify ISSN ↗2212-4063Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 99 / 151 | 34th | Q3 |
| Cardiology and Cardiovascular Medicine | 271 / 409 | 33rd | Q3 |
| Pharmacology | 246 / 328 | 25th | Q3 |
| Molecular Medicine | 159 / 179 | 11th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q3, CiteScore 1.8.
Cardiovascular and Hematological Disorders - Drug Targets is Q3 in Hematology (rank 99 of 151), Q3 in Cardiology and Cardiovascular Medicine (rank 271 of 409) and Q3 in Pharmacology (rank 246 of 328), by CiteScore 2025. It is ranked in 4 subject areas in all.
Cardiovascular and Hematological Disorders - Drug Targets is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 1.8, quartile Q3, 34th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.236, quartile Q4, with an H-index of 48.
Cardiovascular and Hematological Disorders - Drug Targets is published by Bentham Science Publishers. Its print ISSN is 1871-529X and its online ISSN is 2212-4063.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cardiovascular and Hematological Disorders - Drug Targets has an h-index of 52 and a 2-year mean of 1.16 citations per paper (OpenAlex). Its Scopus CiteScore is 1.8, quartile Q3. On 2-year citations it ranks #83 of 148 Scopus journals in Hematology.
Cardiovascular and Hematological Disorders - Drug Targets published 42 papers in 2025; its busiest recent year was 2018 with 59. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2024–2026), authors are most often from India (39.6%), United States (15.4%) and Iran (9.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.